JAK1 and non-small cell lung carcinoma: Finally, immune checkpoints such as PD-1, CTLA4, LAG3 and TIM3 were strongly connected with the level of JAK1 expression, which suggested that JAK1 may play a role in immunotherapy for NSCLC.